Please assess the completion status of the following clinical trial:

Trial Title: Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Japanese participant diagnosed with compensated CHC GT 1~* Absence of ascites, bleeding esophageal varices, hepatic encephalopathy, or other signs or symptoms of advanced liver disease.~* IFN treatment naive~* No evidence of cirrhosis~Exclusion criteria:~* Co-infection with human immunodeficiency virus (HIV)~* Positive hepatitis B surface antigen or other evidence of active hepatitis B infection~* Any other condition that is contraindicated or for which caution is required for treatment with peg-IFN or RBV~* Any condition or pre-study laboratory abnormality, or history of any illness, that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering the study drugs, peg-IFN and RBV, to the participant.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Vaniprevir 12 Week Arm (Type: EXPERIMENTAL): Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) and then 12 weeks of placebo to vaniprevir along with 24 weeks of treatment with peg-IFN and RBV.
- Vaniprevir 24 Week Arm (Type: EXPERIMENTAL): Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV.
- Control Arm (Type: ACTIVE_COMPARATOR): Participants on this arm receive 24 weeks of treatment with placebo to vaniprevir along with 48 weeks of treatment with peg-IFN and RBV.

Based on this trial design, predict the completion outcome and termination type (if applicable).